| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.002 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.002 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.086 | 0.003 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.003 |